JP6092113B2 - セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 - Google Patents

セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 Download PDF

Info

Publication number
JP6092113B2
JP6092113B2 JP2013538866A JP2013538866A JP6092113B2 JP 6092113 B2 JP6092113 B2 JP 6092113B2 JP 2013538866 A JP2013538866 A JP 2013538866A JP 2013538866 A JP2013538866 A JP 2013538866A JP 6092113 B2 JP6092113 B2 JP 6092113B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
diketopiperazine
sumatriptan
composition according
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013538866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545748A (ja
JP2013545748A5 (https=
Inventor
レオーネ−ベイ、アンドレア
ダブリュ ストーウェル、グレイソン
ダブリュ ストーウェル、グレイソン
ジェイ ガーネリ、ジョセフ
ジェイ ガーネリ、ジョセフ
エム カールソン、ドーン
エム カールソン、ドーン
グラント、マーシャル
シー スマットニー、チャド
シー スマットニー、チャド
Original Assignee
マンカインド コーポレイション
マンカインド コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マンカインド コーポレイション, マンカインド コーポレイション filed Critical マンカインド コーポレイション
Publication of JP2013545748A publication Critical patent/JP2013545748A/ja
Publication of JP2013545748A5 publication Critical patent/JP2013545748A5/ja
Application granted granted Critical
Publication of JP6092113B2 publication Critical patent/JP6092113B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2013538866A 2010-11-09 2011-11-09 セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物 Active JP6092113B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41177510P 2010-11-09 2010-11-09
US61/411,775 2010-11-09
US41233910P 2010-11-10 2010-11-10
US61/412,339 2010-11-10
PCT/US2011/060057 WO2012064892A1 (en) 2010-11-09 2011-11-09 Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017021017A Division JP6458064B2 (ja) 2010-11-09 2017-02-08 ジケトピペラジンを含む治療のための組成物

Publications (3)

Publication Number Publication Date
JP2013545748A JP2013545748A (ja) 2013-12-26
JP2013545748A5 JP2013545748A5 (https=) 2016-04-07
JP6092113B2 true JP6092113B2 (ja) 2017-03-08

Family

ID=45048258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013538866A Active JP6092113B2 (ja) 2010-11-09 2011-11-09 セロトニン受容体アゴニストおよびジケトピペラジンを含む偏頭痛治療のための組成物
JP2017021017A Active JP6458064B2 (ja) 2010-11-09 2017-02-08 ジケトピペラジンを含む治療のための組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017021017A Active JP6458064B2 (ja) 2010-11-09 2017-02-08 ジケトピペラジンを含む治療のための組成物

Country Status (10)

Country Link
EP (2) EP2637657B1 (https=)
JP (2) JP6092113B2 (https=)
KR (1) KR101931392B1 (https=)
CN (2) CN103200940A (https=)
AU (1) AU2011326529B2 (https=)
BR (1) BR112013011549B1 (https=)
CA (1) CA2817337C (https=)
ES (1) ES2732818T3 (https=)
MX (2) MX340112B (https=)
WO (1) WO2012064892A1 (https=)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko) 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
EP3587404B1 (en) 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
CN104922127B (zh) * 2013-11-27 2016-11-30 广州安健实业发展有限公司 式2化合物在制备治疗和/或预防偏头痛及其并发症的药物中的用途
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
KR20180002750A (ko) * 2015-05-01 2018-01-08 키비타스 테라퓨틱스, 인코포레이티드. 폐 전달용 졸미트립탄 분말
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AU2016287582B2 (en) 2015-07-02 2020-03-12 Civitas Therapeutics, Inc. Triptan powders for pulmonary delivery
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
GB201709459D0 (en) * 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
US11135379B2 (en) 2019-02-15 2021-10-05 Bn Intellectual Properties, Inc. Method of delivering pharmaceutical products
US11364225B2 (en) * 2019-08-21 2022-06-21 Bn Intellectual Properties, Inc. Pharmaceutical formulation for treating symptoms of migraine and cluster headaches, and method of using the same

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
GB9827145D0 (en) * 1998-12-09 1999-02-03 Co Ordinated Drug Dev Improvements in or relating to powders
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
CN1176649C (zh) * 2002-10-16 2004-11-24 上海医药工业研究院 舒马普坦干粉吸入剂及其制备方法
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP1986679B1 (en) * 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
JP5813323B2 (ja) * 2007-10-24 2015-11-17 マンカインド コーポレイション 活性薬剤の送達方法
EP2211842B1 (en) * 2007-10-24 2015-08-12 MannKind Corporation An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
CA2728808A1 (en) * 2008-02-01 2009-08-06 Vectura Limited Pulmonary formulations of triptans
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统

Also Published As

Publication number Publication date
JP2013545748A (ja) 2013-12-26
MX340112B (es) 2016-06-27
JP2017110026A (ja) 2017-06-22
ES2732818T3 (es) 2019-11-26
EP2637657A1 (en) 2013-09-18
KR20140008314A (ko) 2014-01-21
JP6458064B2 (ja) 2019-01-23
WO2012064892A1 (en) 2012-05-18
EP2637657B1 (en) 2019-05-22
EP3536368A1 (en) 2019-09-11
EP3536368B1 (en) 2025-09-17
CN103200940A (zh) 2013-07-10
BR112013011549A2 (pt) 2017-07-25
AU2011326529A1 (en) 2013-05-02
AU2011326529B2 (en) 2015-07-30
CN107854454A (zh) 2018-03-30
MX376862B (es) 2025-03-07
CA2817337A1 (en) 2012-05-18
MX2013005294A (es) 2013-12-06
KR101931392B1 (ko) 2018-12-20
BR112013011549B1 (pt) 2022-01-04
CA2817337C (en) 2020-04-14

Similar Documents

Publication Publication Date Title
JP6458064B2 (ja) ジケトピペラジンを含む治療のための組成物
US20200405731A1 (en) Method and composition for administering prostaglandins
JP6491658B2 (ja) 熱安定性乾燥粉末医薬組成物及び方法
US8642548B2 (en) Val (8) GLP-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
JP6018640B2 (ja) 疼痛を緩和するのに有効な鎮痛組成物並びに当該組成物を含む乾燥粉末及び乾燥粉末薬剤輸送システム
JP2016006082A (ja) 非対称置換ジケトピペラジン及び微粒子組成物
AU2005277041A1 (en) Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery
JP2006249099A (ja) 持続放出特性を有する吸入用粒子
Tandon et al. Insulin therapy for diabetes epidemic: a patent review
US20240390274A1 (en) Method and composition for treating obesity
AU2017248512B2 (en) Method and composition for treating migraines
HK40014359A (en) Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
HK1189503A (en) Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
HK1189503B (en) Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
AU2012203627B2 (en) Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141106

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150818

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151217

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160118

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20160215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161121

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170110

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170208

R150 Certificate of patent or registration of utility model

Ref document number: 6092113

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250